Johnson & Johnson announces FDA approval for THERMOCOOL SMARTTOUCH SF

Johnson & Johnson announced that the U.S. Food and Drug Administration approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform, an integrated catheter ablation solution that enables electrophysiologists to deliver both radiofrequency and pulsed field energy through a single catheter. Built on the THERMOCOOL SMARTTOUCH SF Platform, which has extensive clinical validation and has treated over one million patients in the U.S., the DE STSF Platform brings pulse field capability to a catheter physicians know and trust. Following FDA approval, first U.S. procedures with the DE STSF Platform are expected to begin this summer as Johnson & Johnson initiates a phased commercial rollout.